News About: Goverment
KFDA to delay final decision of IPA safety
It will take time to decide the safety of isopropylantipyrine (IPA), a substance used to kill pain.
The Korea Food and Drug Administration’s Central Pharmaceutical Deliberation Committee will finally assess the IPA...
KFDA seeking more business-friendly policies
The Korea Food and Drug Administration unveiled its plan to rationalize a number of regulations under the new government’s deregulation pledges.
Such pledges have been gaining good marks from CEOs and executives in...
Drugmakers to be under pressure to lower drug costs
Domestic and foreign pharmaceutical firms will be obliged to reduce prices of insurance-covered drugs as the Health Insurance Review and Assessment Service is set to evaluate the economic effectiveness of 3,000 medici...
3,111 items to be re-evaluated in 2009
The Korea Food and Drug Administration announced that a total of 3,111 drugs will be re-evaluated this year under the provisions of the Korea Pharmaceutical Affairs Laws.
Of the 3,111 items, the number of re-assess...
Narcolepsy should be included in list of rare and intractable diseases, lawmaker says
Rep. Shin Sang-jin of the ruling Grand National Party has presented a petition to the National Assembly that narcolepsy must be included in a list of rare and intractable diseases for better treatment.
If the lawma...
7 drug makers fined for illicit rebates
The country’s corporate watchdog said on January 15 that it has imposed a combined 20.4 billion won in fines on seven pharmaceutical companies for unfair trading practices, including the provision of illegal rebates t...
KFDA to set aside 50.3 billion for safety research projects
The Korea Food and Drug Administration plans to spend 50.3 billion won for promotion of 146 safety research projects related to drugs, foods, medical devices this year.
In an information session on January 15, a KF...
Deregulation to revitalize OTC market
OTC drugmakers is breathing a sigh of relief as the Korea Food and Drug Administration is actively moving ahead to deregulate validation rules governing OTC products with standardized dosage and formulation method.
...
KFDA approves Bausch & Lomb’s loteprednol etabonate 0.5%, 0.2%
The Korea Food and Drug Administration has given a green light to Bausch & Lomb’s loteprednol etabonate 0.5% and 0.2% for treatment of allergic disease.
Loteprednol etabonate 0.2% ophthalmic suspension is used for ...
1% hike in health insurance premium totals 261 billion won in medical expenditure
1% hike in health insurance premium totals 261 billion won in medical expenditure
The total healthcare expenditure will become 261.5 billion won if the health insurance premium increases by 1.00 percent point in ...
